<DOC>
	<DOCNO>NCT01696487</DOCNO>
	<brief_summary>The spectrum NAFLD emerge epidemic range steatosis steatohepatitis ( NASH ) , cirrhosis hepatocellular carcinoma ( HCC ) . Disease progression poorly understood treatment option limit . Fructose overconsumption associate gut permeability progression NAFLD . To unravel mechanism fructose-induced intestinal change , volunteer receive 4-week fructose challenge prior assessment intestinal permeability/translocation use endomicroscopy , sugar probe , serum marker intestinal damage , inflammation , iron/copper homeostasis histological/molecular analysis intestinal biopsy . Findings volunteer compare liver patient undergo study procedure without fructose challenge . Translational vitro experiment explore cellular response fructose endotoxin . This project provide novel insight dietary induce alteration gut integrity progression NAFLD NASH .</brief_summary>
	<brief_title>Impact Fructose Consumption Intestinal Permeability Non-alcoholic Fatty Liver Disease ( NAFLD ) - Pilot Study .</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Healthy men woman 18 85 , disease history , intake regular medication . 2 . Patients confirm ( least one image positive ) intrahepatic fat accumulation ( NAFL ) , male female 3 . Patients confirm NASH ( biopsy within 6 month prior study ) , male female 4 . Diagnosed HCV , genotype 1 , male female Signed inform consent General exclusion criterion ( group ) 1 . Pregnancy lactation 2 . Imprisoned person 3 . Inflammatory bowel condition ( celiac disease , Crohn 's disease , ulcerative colitis ) 4 . Prior bariatric surgery 5 . Alcoholic steatohepatitis and/or alcohol consumption &gt; 140 gramms per week ( &gt; 30g/day ) 6 . Other liver disease ( autoimmune , genetic , cholestatic , Wilson disease , WeberChristian disease , partial lipodystrophy face spar type , abetalipoproteinemia , jejunal diverticulosis bacterial overgrowth . ) 7 . Virus hepatitis ( A , B , C ) ( except group ( 4 ) : define HCV , genotype 1 ) 8 . Known allergic reaction drug use ( see material method ) 9 . Intake drug know accumulate intrahepatic lipid ( e.g . steroids/glucocorticoids , tamoxifen , amiodarone , perhexiline maleate , synthetic estrogen , antiretroviral agent , tetracycline , minocycline , certain pesticide , methotrexate ) 10 . Intake drug know drive fibrosis/cirrhosis ( e.g . azathioprine , oral contraceptive pill ) 11 . Inability contraindication perform study procedure 12 . General absolute endoscopy contraindication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>non-alcoholic fatty liver disease</keyword>
	<keyword>non-alcoholic steatohepatitis</keyword>
	<keyword>NAFLD</keyword>
	<keyword>NASH</keyword>
</DOC>